BLFS · As filed with the SEC

Biolife Solutions cash flow statement, by quarter

The statement as Biolife Solutions presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Unaudited Condensed Consolidated Statements of Cash Flows · USD thousands

USD thousands	Q2 2026^† 3 months ended Jun 30, 2026	Q1 2026 3 months ended Mar 31, 2026	Q4 2025^† 3 months ended Dec 31, 2025	Q3 2025^† 3 months ended Sep 30, 2025
Cash flows from operating activities
Net income (loss)	45,104^†	1,186	11,070^†	621^†
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	411^†	374	261^†	636^†
Amortization of intangible assets	398^†	325	325^†	699^†
Stock-based compensation	3,854^†	4,806	7,077^†	5,904^†
Non-cash lease expense	1,849^†	(188)	—	1,323^†
Deferred income tax (benefit) expense	(42,431)^†	9	0^†	14^†
Change in fair value of equity investment and other	—	—	(942)^†	(41)^†
Accretion of available-for-sale investments	(75)^†	(122)	(201)^†	(230)^†
Gain on disposal of assets held for rent, net	0^†	0	0^†	167^†
Loss on disposal of property and equipment, net	—	—	11^†	0^†
IPR&D expense	—	—	0^†	0^†
Loss on disposal of Global Cooling	—	—	—	0^†
Change in operating assets and liabilities
Accounts receivable, trade, net	2,405^†	(5,104)	1,938^†	(782)^†
Inventories	(2,757)^†	(2,679)	(2,331)^†	(197)^†
Prepaid expenses and other assets	(246)^†	3,218	(462)^†	(3,000)^†
Accounts payable	(1,370)^†	2,206	(952)^†	(679)^†
Accrued expenses and other current liabilities	(755)^†	(4,400)	680^†	1,564^†
Sales taxes payable	(39)^†	(148)	(1,385)^†	105^†
Other	0^†	26	264^†	0^†
Net cash provided by operating activities	6,348^†	(491)	4,916^†	6,104^†
Cash flows from investing activities
Purchases of available-for-sale securities	(14,925)^†	(20,430)	(36,670)^†	(13,090)^†
Proceeds from sale of available-for-sale securities	2,359^†	2,331	3,238^†	1,836^†
Maturities of available-for-sale securities	12,150^†	16,436	15,412^†	10,962^†
Purchases of assets held for rent	0^†	0	(101)^†	(373)^†
Purchases of property and equipment	—	—	—	(3,302)^†
Purchases of property and equipment	(1,043)^†	(167)	—	—
Investment in IPR&D	—	—	0^†	0^†
Investment in convertible promissory note	—	—	0^†	—
Payments on divestiture of Global Cooling	—	—	0^†	0^†
Net cash used in investing activities	(1,579)^†	(1,830)	1,137^†	(5,967)^†
Cash flows from financing activities
Proceeds from exercises of common stock options	3^†	190	0^†	0^†
Proceeds from financed insurance premium	—	—	0^†	—
Payments on term loans	(2,500)^†	(2,500)	(2,500)^†	(2,500)^†
Payments on equipment loans	—	—	0^†	0^†
Payment of tax withholding on vesting of shares	(1,097)^†	(5,588)	—	—
Payments on financed insurance premium	0^†	0	0^†	(67)^†
Other	0^†	3	4^†	9^†
Net cash used in financing activities	(3,594)^†	(7,895)	(2,496)^†	(2,558)^†
Net decrease in cash and cash equivalents	1,175^†	(10,216)	3,557^†	(2,421)^†
Cash and cash equivalents – beginning of period	—	—	29,481	31,902
Cash and cash equivalents – beginning of period	22,822	33,038	—	31,902
Effects of currency translation on cash and cash equivalents	—	—	0^†	0^†
Cash and cash equivalents – end of period	—	—	—	29,481
Cash and cash equivalents – end of period	23,997	22,822	33,038	—
Non-cash investing and financing activities
Purchase of property and equipment not yet paid	102^†	58	(450)^†	360^†
Assets acquired under operating leases	—	—	0^†	0^†
Unrealized gains (losses) on available-for-sale securities	(91)^†	(252)	2^†	59^†
Unrealized gain on currency translation	—	—	0^†	0^†
Non-cash acquisition of PanTHERA	—	—	0^†	0^†
Cash interest paid	30^†	73	118^†	164^†

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.